|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANKFY1 |
Gene summary for ANKFY1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANKFY1 | Gene ID | 51479 |
| Gene name | ankyrin repeat and FYVE domain containing 1 | |
| Gene Alias | ANKHZN | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9P2R3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51479 | ANKFY1 | LZE4T | Human | Esophagus | ESCC | 8.77e-08 | 2.46e-01 | 0.0811 |
| 51479 | ANKFY1 | LZE8T | Human | Esophagus | ESCC | 2.22e-05 | 1.00e-01 | 0.067 |
| 51479 | ANKFY1 | LZE24T | Human | Esophagus | ESCC | 3.45e-11 | 2.54e-01 | 0.0596 |
| 51479 | ANKFY1 | LZE21T | Human | Esophagus | ESCC | 1.81e-06 | 2.56e-01 | 0.0655 |
| 51479 | ANKFY1 | P1T-E | Human | Esophagus | ESCC | 4.81e-06 | 3.38e-01 | 0.0875 |
| 51479 | ANKFY1 | P2T-E | Human | Esophagus | ESCC | 1.20e-12 | 2.41e-01 | 0.1177 |
| 51479 | ANKFY1 | P4T-E | Human | Esophagus | ESCC | 7.07e-13 | 2.54e-01 | 0.1323 |
| 51479 | ANKFY1 | P8T-E | Human | Esophagus | ESCC | 1.65e-19 | 3.00e-01 | 0.0889 |
| 51479 | ANKFY1 | P9T-E | Human | Esophagus | ESCC | 3.95e-13 | 2.09e-01 | 0.1131 |
| 51479 | ANKFY1 | P10T-E | Human | Esophagus | ESCC | 2.22e-11 | 1.91e-01 | 0.116 |
| 51479 | ANKFY1 | P11T-E | Human | Esophagus | ESCC | 4.38e-11 | 4.83e-01 | 0.1426 |
| 51479 | ANKFY1 | P12T-E | Human | Esophagus | ESCC | 1.76e-15 | 2.78e-01 | 0.1122 |
| 51479 | ANKFY1 | P15T-E | Human | Esophagus | ESCC | 1.63e-06 | 1.65e-01 | 0.1149 |
| 51479 | ANKFY1 | P16T-E | Human | Esophagus | ESCC | 2.69e-13 | 2.11e-01 | 0.1153 |
| 51479 | ANKFY1 | P17T-E | Human | Esophagus | ESCC | 4.43e-07 | 2.25e-01 | 0.1278 |
| 51479 | ANKFY1 | P20T-E | Human | Esophagus | ESCC | 4.59e-10 | 1.94e-01 | 0.1124 |
| 51479 | ANKFY1 | P21T-E | Human | Esophagus | ESCC | 1.27e-09 | 2.10e-01 | 0.1617 |
| 51479 | ANKFY1 | P22T-E | Human | Esophagus | ESCC | 1.14e-15 | 1.54e-01 | 0.1236 |
| 51479 | ANKFY1 | P23T-E | Human | Esophagus | ESCC | 9.99e-11 | 2.12e-01 | 0.108 |
| 51479 | ANKFY1 | P24T-E | Human | Esophagus | ESCC | 3.84e-12 | 2.41e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004214722 | Oral cavity | EOLP | retrograde transport, endosome to Golgi | 21/2218 | 91/18723 | 1.89e-03 | 1.21e-02 | 21 |
| GO:00610252 | Oral cavity | EOLP | membrane fusion | 31/2218 | 163/18723 | 5.09e-03 | 2.67e-02 | 31 |
| GO:009016011 | Oral cavity | EOLP | Golgi to lysosome transport | 5/2218 | 11/18723 | 5.79e-03 | 2.94e-02 | 5 |
| GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
| GO:00160507 | Prostate | BPH | vesicle organization | 82/3107 | 300/18723 | 1.64e-06 | 2.78e-05 | 82 |
| GO:00164828 | Prostate | BPH | cytosolic transport | 51/3107 | 168/18723 | 6.56e-06 | 9.53e-05 | 51 |
| GO:003010010 | Prostate | BPH | regulation of endocytosis | 60/3107 | 211/18723 | 1.06e-05 | 1.45e-04 | 60 |
| GO:00068928 | Prostate | BPH | post-Golgi vesicle-mediated transport | 34/3107 | 104/18723 | 4.14e-05 | 4.43e-04 | 34 |
| GO:00161978 | Prostate | BPH | endosomal transport | 62/3107 | 230/18723 | 4.54e-05 | 4.77e-04 | 62 |
| GO:00070349 | Prostate | BPH | vacuolar transport | 46/3107 | 157/18723 | 4.86e-05 | 5.07e-04 | 46 |
| GO:00458079 | Prostate | BPH | positive regulation of endocytosis | 32/3107 | 100/18723 | 1.09e-04 | 9.95e-04 | 32 |
| GO:00070417 | Prostate | BPH | lysosomal transport | 32/3107 | 114/18723 | 1.42e-03 | 8.47e-03 | 32 |
| GO:0048548 | Prostate | BPH | regulation of pinocytosis | 6/3107 | 12/18723 | 7.73e-03 | 3.39e-02 | 6 |
| GO:00421475 | Prostate | BPH | retrograde transport, endosome to Golgi | 24/3107 | 91/18723 | 1.19e-02 | 4.82e-02 | 24 |
| GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
| GO:001605012 | Prostate | Tumor | vesicle organization | 87/3246 | 300/18723 | 3.44e-07 | 7.71e-06 | 87 |
| GO:001648213 | Prostate | Tumor | cytosolic transport | 54/3246 | 168/18723 | 2.01e-06 | 3.46e-05 | 54 |
| GO:000703414 | Prostate | Tumor | vacuolar transport | 48/3246 | 157/18723 | 3.18e-05 | 3.78e-04 | 48 |
| GO:003010015 | Prostate | Tumor | regulation of endocytosis | 60/3246 | 211/18723 | 4.05e-05 | 4.62e-04 | 60 |
| GO:000689213 | Prostate | Tumor | post-Golgi vesicle-mediated transport | 35/3246 | 104/18723 | 4.14e-05 | 4.70e-04 | 35 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANKFY1 | SNV | Missense_Mutation | c.470T>C | p.Met157Thr | p.M157T | Q9P2R3 | protein_coding | tolerated(0.41) | benign(0.023) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ANKFY1 | SNV | Missense_Mutation | c.793N>T | p.His265Tyr | p.H265Y | Q9P2R3 | protein_coding | deleterious(0) | benign(0.421) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ANKFY1 | SNV | Missense_Mutation | rs768383868 | c.923G>A | p.Arg308Gln | p.R308Q | Q9P2R3 | protein_coding | tolerated(0.58) | benign(0.003) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ANKFY1 | SNV | Missense_Mutation | novel | c.1851N>A | p.Asn617Lys | p.N617K | Q9P2R3 | protein_coding | tolerated(0.27) | benign(0.124) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ANKFY1 | SNV | Missense_Mutation | rs745379002 | c.712N>A | p.Asp238Asn | p.D238N | Q9P2R3 | protein_coding | tolerated(0.08) | benign(0.311) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ANKFY1 | SNV | Missense_Mutation | c.2159G>C | p.Gly720Ala | p.G720A | Q9P2R3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ANKFY1 | insertion | Nonsense_Mutation | novel | c.2211_2212insGCTGCCTGAGCTCCTGTAGTCACG | p.Ala737_Leu738insAlaAlaTerAlaProValValThr | p.A737_L738insAA*APVVT | Q9P2R3 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ANKFY1 | insertion | Nonsense_Mutation | novel | c.2161_2162insTCTTGGCATGCCAGTAGCCGGCTTGACTTTCACAGTTAAGGTTATCA | p.Ala721ValfsTer6 | p.A721Vfs*6 | Q9P2R3 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| ANKFY1 | insertion | Nonsense_Mutation | novel | c.915_916insACGTAGACATCAAAGAGAGAATCTA | p.Leu306ThrfsTer2 | p.L306Tfs*2 | Q9P2R3 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| ANKFY1 | insertion | Frame_Shift_Ins | novel | c.3043_3044insTTTATCCACCATCACAGAGTTCAGAAAATTCT | p.Asn1015IlefsTer31 | p.N1015Ifs*31 | Q9P2R3 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |